Showing results (61-70 of 284) with videos related to
Sort By:
Pageof 29
Parkinsonism & Related Disorders|July 1, 2008
Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's diseaseManfred Gerlach, Peter Riederer, Kay L DoubleJournal of Neural Transmission (Vienna, Austria : 1996)|September 14, 2012
Considerations for measuring iron in post-mortem tissue of Parkinson's disease patientsDominic J Hare, Manfred Gerlach, Peter RiedererJournal of Alzheimer'S Disease : JAD|August 18, 2006
Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated ratEdna Grünblatt, Eleni Koutsilieri, Siegfried Hoyer, et al.Cell and Tissue Research|September 15, 2004
Redox imbalanceDaniela Berg, Moussa B H Youdim, Peter RiedererEuropean Archives of Psychiatry and Clinical Neuroscience|June 22, 2006
Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distributionJohannes Kornhuber, Jens Wiltfang, Peter Riederer, et al.Biomedicines|January 8, 2025
Metabolic Dysfunction in Parkinson's Disease: Unraveling the Glucose-Lipid ConnectionJeswinder Sian-Hulsmann, Peter Riederer, Tanja Maria MichelPharmacopsychiatry|January 26, 2022
Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence?Juliane K Mueller, Peter Riederer, Walter E MüllerJournal of Neural Transmission (Vienna, Austria : 1996)|February 24, 2021
Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentialsWojciech Danysz, Andrzej Dekundy, Astrid Scheschonka, et al.Parkinsonism & Related Disorders|October 9, 2007
Relating mode of action to clinical practice: dopaminergic agents in Parkinson's diseasePeter Riederer, Manfred Gerlach, Thomas Müller, et al.Therapeutic Drug Monitoring|June 7, 2013
Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapineElnaz Ostad Haji, Stefanie Wagner, Mirijam Fric, et al.Pageof 29